CoChat

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in the emerging class of GLP-1R NPAs is orforglipron, which is in clinical development for treating type 2 diabetes and obesity. Here, we characterized the pharmacological properties of orforglipron in comparison with peptide-based GLP-1R agonists and other NPAs. Competition binding experiments using either [ 125 I]GLP-1(7-36)NH 2 or [ 3 H]orforglipron indicated that orforglipron is a high-affinity [inhibition constant ( K i ) = 1 nM], selective ligand of the human GLP-1R. Signal transduction assays showed that orforglipron has low intrinsic efficacy for effector activation and negligible β-arrestin recruitment. To evaluate GLP-1R engagement in vivo, mice expressing the human GLP-1R were administered orforglipron and subjected to a glucose tolerance test. Predicted receptor occupancy was calculated using the receptor K i value of orforglipron and its unbound concentration in vivo that reduces hyperglycemia. These experiments revealed that low GLP-1R occupancy by orforglipron is sufficient to yield a full biological response. Moreover, in a model where CRISPR-Cas9 gene editing was used to sensitize the rat GLP-1R ( Glp1r S33W ) to GLP-1R NPAs, target engagement by orforglipron in the pancreas and brain was consistent with peptide-based GLP-1R agonists. Diet-induced obesity in Glp1r S33W rats enabled studies showing weight loss in animals orally administered orforglipron versus subcutaneous injection of GLP-1R agonist semaglutide. Furthermore, crossover studies indicated oral orforglipron can sustain efficacy initiated by parenteral semaglutide. The pharmacological properties of orforglipron may inform targeting of other peptide receptors with NPAs.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.adp5765

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Research works printed but not linked: 1

  1. T. P. Kenakin A Pharmacology Primer: Techniques for More Effective and Strategic Drug (Academic Press ed. 6 2022).

Cited by

See all 53

Metadata

Authors
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., O’Farrell, L. S., Hewitt, N., Ruble, J. C., Padgett, L. R., Woerly, E. M., Peterson, J. A., Coskun, T., Liu, Z., Coutant, D. E., Ai, M., Emmerson, P. J., Sangwung, P., & Willard, F. S.
Affiliations
  • Eli Lilly (United States) (US)
  • Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Corresponding author
Sloop, Kyle W.
Venue
Science Translational Medicine
Published
2024-12-18
Volume
16
Issue
778
Pages
eadp5765-eadp5765
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W4405516956
Cited by
52
References
43
Citations by year
2026: 36 · 2025: 15 · 2024: 1
FWCI
17.01
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
orforglipron, GLP-1 receptor, type 2 diabetes, obesity, receptor occupancy, target engagement, semaglutide, glucose tolerance, beta-arrestin, intrinsic efficacy, oral bioavailability, crossover design, metabolic disorders
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Glucose Tolerance Test, Humans, Male, Mice, Inbred C57BL, Oxadiazoles, Signal Transduction, Fluorine Compounds, Mice, Rats, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. https://app.cochat.ai/papers/10.1126/scitranslmed.adp5765
The paper
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., O’Farrell, L. S., Hewitt, N., Ruble, J. C., Padgett, L. R., Woerly, E. M., Peterson, J. A., Coskun, T., Liu, Z., Coutant, D. E., . . . Willard, F. S. (2024). The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adp5765

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.